<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553423</url>
  </required_header>
  <id_info>
    <org_study_id>06GS013MED</org_study_id>
    <nct_id>NCT00553423</nct_id>
  </id_info>
  <brief_title>Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage</brief_title>
  <official_title>Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the role of lactulose in prevention of clinically overt hepatic encephalopathy
      (HE) in the setting of acute upper gastrointestinal bleeding in cirrhotic patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Variceal hemorrhage occurs in 25 to 35 % of patients with cirrhosis and accounts for 80 to
      90% of bleeding episodes in these patients. Around 25-30 percent of patients develop hepatic
      encephalopathy. Development of hepatic encephalopathy in patients with gastrointestinal bleed
      can cause increase morbidity with higher hospital costs in these patients. To date no
      randomized trial has been done in terms of prevention of encephalopathy in gastrointestinal
      hemorrhage. One trial has compared lactulose in combination with antibiotic against mannite,
      showed equal efficacy in both groups. No study has been done evaluate the efficacy of
      lactulose in prevention of encephalopathy in these patients.

      We hypothesize that prophylactic use of Lactulose decreases the risk of development of
      hepatic encephalopathy with upper GI bleed in cirrhotics.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">November 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Clinically Overt Hepatic Encephalopathy</measure>
    <time_frame>48hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death, hospital stay</measure>
    <time_frame>48hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Hepatocerebral Encephalopathy</condition>
  <condition>Portal-Systemic Encephalopathy</condition>
  <condition>Encephalopathy, Hepatic</condition>
  <condition>Encephalopathy, Hepatocerebral</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactulose 30 ml q6h for 48 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 30 ml q6 hrly for 48hrs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>Lactulose 30 ml q6h for 48 hrs</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 30 ml q6hrly for 48 hrs</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  All acute gastrointestinal bleeding in cirrhotics without hepatic encephalopathy at
             the time of admission in ER

        Exclusion Criteria:

          -  Increased Î±-fetoprotein level/ Documented hepatoma

          -  Portal or hepatic vein thrombosis

          -  Large-volume or tense ascites requiring repeated therapeutic paracentesis

          -  Serious recurrent or ongoing co morbid illness (e.g., severe renal, cardiac, or
             respiratory failure; sepsis)

          -  Pregnancy

          -  Not willing to give consent to participate in the study

          -  Patients who are unable to read and write

          -  ER arrival time &gt; 12 hrs from index bleed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahid Majid, FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aga Khan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Salih, FCPS</last_name>
    <role>Study Director</role>
    <affiliation>Aga Khan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shahid Ahmed, FCPS</last_name>
    <role>Study Director</role>
    <affiliation>Aga Khan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wasim Jafri, FCPS</last_name>
    <role>Study Chair</role>
    <affiliation>Aga Khan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahid Majid, FCPS</last_name>
    <phone>9221-4930051</phone>
    <phone_ext>4447</phone_ext>
    <email>shahid.majid@aku.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammad Salih, FCPS</last_name>
    <phone>9221-4930051</phone>
    <phone_ext>4528</phone_ext>
    <email>mohammad.salih@aku.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aga Khan university</name>
      <address>
        <city>Karachi</city>
        <state>Sind</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shahid Majid, FCPS</last_name>
      <phone>9221-4930051</phone>
      <phone_ext>4447</phone_ext>
      <email>shahid.majid@aku.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mohammad Salih, FCPS</last_name>
      <phone>9221-4930051</phone>
      <phone_ext>4528</phone_ext>
      <email>mohammad.salih@aku.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shahid Majid, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammad Salih, FCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shahid Ahmed, FCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wasim Jafri, FRCP, FACG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <state>Sind</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahid Majid, FCPS</last_name>
      <phone>9221-4930051</phone>
      <phone_ext>4447</phone_ext>
      <email>shahid.majid@aku.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mohammad Salih, FCPS</last_name>
      <phone>9221-4930051</phone>
      <phone_ext>4528</phone_ext>
      <email>mohammad.salih@aku.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2007</study_first_posted>
  <last_update_submitted>November 2, 2007</last_update_submitted>
  <last_update_submitted_qc>November 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

